Guangdong Hec Technology Holding Co Ltd
SSE:600673
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (52), the stock would be worth ¥23.03 (31% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 75 | ¥33.22 |
0%
|
| 3-Year Average | 52 | ¥23.03 |
-31%
|
| 5-Year Average | 38.7 | ¥17.13 |
-48%
|
| Industry Average | 18.3 | ¥8.09 |
-76%
|
| Country Average | 18.3 | ¥8.08 |
-76%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
G
|
Guangdong Hec Technology Holding Co Ltd
SSE:600673
|
98.2B CNY | 75 | 356.5 | |
| CN |
|
Shandong Hongchuang Aluminum Industry Holding Co Ltd
SZSE:002379
|
328.4B CNY | 13.7 | 18.4 | |
| CN |
C
|
China Hongqiao Group Ltd
HKEX:1378
|
331.1B HKD | 6.7 | 12.5 | |
| CN |
A
|
Aluminum Corp of China Ltd
OTC:ALMMF
|
40.3B USD | 7.1 | 18.8 | |
| CN |
|
Aluminum Corporation of China Ltd
SSE:601600
|
200B CNY | 5.2 | 13.7 | |
| IN |
|
Hindalco Industries Ltd
NSE:HINDALCO
|
2.4T INR | 9.5 | 14.8 | |
| NO |
|
Norsk Hydro ASA
OSE:NHY
|
207.9B NOK | 8.7 | 30.3 | |
| MY |
|
Press Metal Aluminium Holdings Bhd
KLSE:PMETAL
|
72B MYR | 21.5 | 34.3 | |
| US |
|
Alcoa Corp
NYSE:AA
|
16.6B USD | 17.6 | 15.9 | |
| CN |
|
Yunnan Aluminium Co Ltd
SZSE:000807
|
112.7B CNY | 11.6 | 13.5 | |
| CN |
|
Tianshan Aluminum Group Co Ltd
SZSE:002532
|
77.7B CNY | 9.7 | 16.1 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 9.8 |
| Median | 18.3 |
| 70th Percentile | 36.5 |
| Max | 266 666.7 |
Other Multiples
Guangdong Hec Technology Holding Co Ltd
Glance View
Nestled in the vibrant economic landscape of China, Guangdong Hec Technology Holding Co Ltd operates with the intricacies of a well-oiled machine in the health sector. The company, with its focal point in pharmaceuticals, has been a significant player in the development, manufacturing, and sale of a variety of medicinal products. Its portfolio spans across anti-infectives, digestive medications, and cardiovascular treatments, amassing a reputation for innovation and quality. The company’s commitment to research and development is palpable, as it consistently invests in state-of-the-art laboratories and collaborations with leading scientific minds. This approach not only fuels its pipeline of groundbreaking therapies but also ensures a steady stream of products ready for market. The company's revenue engine hums efficiently through a strategic blend of domestic and international market penetration. By leveraging an extensive distribution network, Guangdong Hec Technology ensures its products reach both regional pharmacies and global pharmaceutical markets. Through meticulous marketing strategies and strategic partnerships, the company has adeptly navigated the complex waters of regulatory compliance and competitive pricing landscapes. Its financial fortitude is further bolstered by a judicious mix of pharmaceutical exports and local sales, highlighting its dual focus on global expansion and domestic consolidation. In this dance of science and commerce, Guangdong Hec Technology continues to solidify its stature, harnessing both innovation and keen business acumen to thrive in the ever-evolving pharmaceutical industry.